In CD19-targeting CAR-T cell therapy for B cell acute lymphocytic leukemia (B-ALL), persistent single-target immunotherapy may induce selection pressure that triggers CD19 gene mutations, leading to reduced or absent surface expression [14,15]. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.